Vasgen

Vasgen is a private, pre-clinical stage biotech developing novel antibody-based inhibitors targeting ADAM proteases for ocular and cancer indications. Its core asset is the AbIMP® platform, designed to overcome historical challenges in inhibiting metzincin proteases. The company is actively seeking investment and partnerships to advance its lead pre-clinical program, with key validation points including proof-of-concept data and grant funding.

AbIMP® platform: Utilizes monoclonal antibodies as selective inhibitors of metzincin proteases, particularly ADAM family sheddases, to overcome challenges of traditional small-molecule inhibition.

Vasgen competes in crowded anti-angiogenic markets dominated by VEGF-targeting biologics (e.g., Roche/Genentech, Regeneron) and a pipeline of next-generation agents. Its differentiation lies in a novel, non-VEGF mechanism targeting ADAM sheddases, a space with limited clinical-stage competition but significant biological validation.